Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

PHASE3CompletedINTERVENTIONAL
Enrollment

642

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

May 11, 2024

Study Completion Date

May 11, 2024

Conditions
Dry Eye SyndromesDry Eye DiseaseKerato Conjunctivitis Sicca
Interventions
DRUG

5% Tavilermide ophthalmic solution

Twice a day topicial dosing

OTHER

Vehicle ophthalmic solution

Twice a day topical dosing

Trial Locations (29)

14618

Rochester Ophthalmological Group, Rochester

16066

Scott & Christie and Associates, Cranberry Township

21078

Seidenberg Protzko Eye Associates, Havre de Grace

24502

Piedmont Eye Center, Lynchburg

27101

James D. Branch, Winston-Salem

27529

Oculus Research, Garner

30339

Eye Consultants of Atlanta, Atlanta

32256

Bowden Eye & Associates, Jacksonville

33773

Shettle Eye Research, Largo

33901

Eye Associates of Fort Myers, Fort Myers

34429

Nature Coast Clinical Research, Crystal River

37215

Toyos Clinic, Nashville

38119

Total Eye Care, Memphis

44115

Abrams Eye Center, Cleveland

46260

Price Vision Group, Indianapolis

63017

Midwest Vision Research Foundation, Chesterfield

63131

Ophthalmology Associates, St Louis

64133

Silverstein Eye Centers, Kansas City

64154

Moyes Eye Center, Kansas City

66762

Kannarr Eye Care, Pittsburg

77034

Advanced Laser Vision & Surgical Institute, Houston

78229

PNV Clinical Research, San Antonio

78738

Lake Travis Eye & Laser Center/Revolution Research, Lakeway

84107

The Eye Institute of Utah, Salt Lake City

85003

Eye Doctors of Arizona, Phoenix

91204

Global Research Management, Glendale

92562

LoBue Laser and Eye Medical Center, Murrieta

92663

Eye Research Foundation, Newport Beach

02888

West Bay Eye Associates, Warwick

All Listed Sponsors
lead

Mimetogen Pharmaceuticals USA, Inc.

INDUSTRY